Sweden: 11 Biosimilar medicines have the same reimbursement process as new chemical drugs in Sweden. Recommendations were based on clinical comparability and lower drug acquisition costs, for the biosimilars versus the originator, and for lipegfilgrastim versus pegfilgrastim. Use of the pegylated forms of filgrastim appear to be restricted to certain situations where their use is considered appropriate.
Beneficial characteristics of biobetters such as convenience of use, in the absence of demonstrated improvements in therapeutic effect, may not be sufficient to justify a premium price to payers. This is seen with pegfilgrastim, a biobetter of filgrastim, where cost savings were demonstrated only in certain circumstances as the price was higher than for biosimilars, and is therefore recommended in multiple countries for restricted use only. Follow-on versions of existing biobetters achieve reimbursement by offering lower drug acquisition costs, as seen with lipegfilgrastim that was developed subsequently as a comparable product to pegfilgrastim. Other biobetters have demonstrated therapeutic benefits, such as improved efficacy observed with pegylated forms of interferon alfa (peginterferon alfa) versus originator interferon alfa, with cost effectiveness considered in their reimbursement. 14 As with biosimilars, payer concerns exist with respect to the need for long-term safety data on biobetters, which may preclude reimbursement on the basis of availability of alternative products. HTA agencies do not currently have any guidance in place on the appraisal of biosmilars or biobetters. 
DISCUSSION

INTRODUCTION
Biosimilars and biobetters are subsequent versions of licensed innovator biotherapeutics. Biosimilars are designed to be similar to an approved originator biologic product, and are expected to demonstrate comparability to the originator product in terms of quality, safety and efficacy; 1 whereas biobetters incorporate intentional modifications to the originator molecular profile with the aim of producing an improved product. 2 This distinction between biosimilars and biobetters has important implications from a regulatory perspective, with biosimilars following class-specific guidance whereas biobetters are considered innovator drugs. Filgrastim, which is recombinant granulocyte-colony stimulating factor, is an example of a biologic drug for which there are biosimilar products. 3 Within this product class are also two products referred to as 'biobetters'  pegfilgrastim and lipegfilgrastim, which are pegylated forms of filgrastim. 4, 5 These pegylated forms are long-acting versions that require a lower frequency of administration compared with originator filgrastim. 6
OBJECTIVE
A qualitative documentary analysis was performed to gain an understanding of the regulatory and reimbursement approaches to the appraisal of biosimilars and biobetters in six European countries using HTA to inform decision making. The filgrastims were examined as there are both biosimilars and biobetters approved in this product class.
METHODS
Within the product class of filgrastim, seven biosimilars, together with pegfilgrastim and lipegfilgrastim, were identified to have been approved in Europe. For each of these drugs, regulatory information and HTA documentation from six European countries, were identified and reviewed for information on the processes of appraisal, the recommendations by indication, and the key factors driving the reimbursement decisions.
The regulatory approval of filgrastim biosimilars requires the demonstration of similarity to originator filgrastims; the specific non-clinical and clinical requirements are detailed in the guidance provided by the European Medicines Agency (EMA) for the development of similar biological medicinal products containing recombinant G-CSF. 7 Biosimilar filgrastims were granted European marketing authorisation based on demonstration of clinical comparability to the originator filgrastim Neupogen  in one indication (reduce duration of neutropenia and occurrence of febrile neutropenia in chemotherapy patients showing cytotoxicity), and extrapolation of the results to all five approved indications. The EMA guidance on biosimilars is not applicable to modified 'biobetter' versions of the drug, such as the pegylated forms of filgrastim. Pegfilgrastim (Neulasta) demonstrated clinical non-inferiority to originator filgrastim in the same indication as above and was approved solely for this indication. The subsequently developed lipegfilgrastim (Lonquex) was approved for the same indication but used pegfilgrastim as the comparator in clinical trials.
Decision drivers identified in the HTA appraisals were (Table 1) :
France: 8 The biosimilars were judged to have equivalent efficacy to the originator filgrastim and were placed in the category of no improvement in medical benefit (ASMR = 5). For the pegylated forms of filgrastim, although there were no improvements in terms of efficacy or safety with respect to filgrastim, benefits were noted in terms of convenience of use and quality of life, leading to a positive recommendation for pegfilgrastim. However, for lipegfilgrastim, an increased risk of mortality in a subgroup of patients was noted, which is being evaluated further in post-marketing studies, resulting in the decision to not recommend in light of the availability of alternative drugs in this product class.
Netherlands: 9 Similarity to the originator as judged by the EMA was accepted as sufficient evidence for the biosimilars and pegfilgrastim to be placed on the reimbursement list (Annex 1a), without undergoing a formal assessment. Lipegfilgrastim was added to this reimbursement list, allowing for interchangeabilty of the originator filgrastim, biosimilar filgrastims, and the pegylated forms of filgrastim within this product cluster on the GVS formulary.
Scotland: 10 Evidence of clinical non-inferiority to the respective comparator was accepted in the appraisal of biosimilars and the pegylated forms of filgrastim. Economic evidence considered for the biosimilars consisted of a costminimisation analysis and a budget impact analysis; cost effectiveness demonstrated in one indication was extrapolated to the other indications. The pegylated forms of filgrastim were considered beneficial in terms of convenience, with cost savings due to lower drug acquisition costs, and recommended for restricted use where a long-acting G-CSF is considered appropriate in line with current clinical practice.
RESULTS
